New medication to treat breathing problems from opioid and polysubstance overdoses.
Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
This study is testing a new medication called ENA-001 that helps people breathe better during opioid or drug overdoses without taking away their pain relief, and it's meant for use in hospitals and emergency situations.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Enalare Therapeutics INC. NIH-funded |
| Lab location | 1 site (Princeton, United States) |
| Project ID | NIH-11191003 on NIH RePORTER |
What this research studies
This research focuses on developing a new medication called ENA-001, which aims to treat respiratory depression caused by opioid or polysubstance overdoses. The medication works by stimulating breathing without reversing pain relief or causing withdrawal symptoms. It is designed for use in both hospital and community settings, making it accessible for emergency situations. The research involves clinical studies to determine the appropriate dosing and effectiveness of ENA-001 in improving respiratory function while maintaining normal oxygen levels.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced an opioid or polysubstance overdose and are in need of respiratory support.
Not a fit: Patients who have not experienced respiratory depression or overdose may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a life-saving treatment option for individuals experiencing respiratory depression due to drug overdoses.
How similar studies have performed: Previous clinical studies have shown promising results with similar approaches, indicating potential for success with this novel treatment.
Where this research is happening
Princeton, United States
- Enalare Therapeutics INC. — Princeton, United States (Active)
Researchers
- Principal investigator: Miller, Thomas L. — Enalare Therapeutics INC.
- Study coordinator: Miller, Thomas L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.